Expanded Dryvax Dilution Study in Previously Vaccinated Adults

Smallpox Clinical Trial

Official title:

A Multicenter, Double Blind, Randomized Dose-response Study of Dryvax Vaccine Against Smallpox in Previously Vaccinated Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00050505
• Other study ID #: 02-007
• Status: Completed
• Phase: Phase 2
• First received: December 10, 2002
• Last updated: December 4, 2014
• Start date: October 2002
• Est. completion date: December 2003

Study information

• Verified date: July 2009
• Source: National Institute of Allergy and Infectious Diseases (NIAID)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationUnited States: Federal Government
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the safety and effect of diluting smallpox vaccine, making a larger number of doses in case smallpox is released into the environment. A total of up to 927 healthy adults between the ages of 32 and 70 years who were already vaccinated against smallpox (but not since 1989) will volunteer for this study for up to 34 weeks and receive different strengths of vaccine. Some subjects may participate for longer if they choose to be revaccinated because the first vaccination does not take. The vaccine will be given by making small cuts in the skin and putting the vaccine into these cuts. After the screening visit, volunteers will be followed through study visits and follow up phone calls. Blood will be collected during some study visits to look at the immune system (body system that fights infection) response.

Description:

The purposes of this multi-center, double blind randomized dose response study are: to evaluate the safety of undiluted Dryvax and Dryvax diluted at 1:5 and 1:10 in adults between the ages of 32 and 70 years who were previously vaccinated but not since 1989 and to define, with very high precision (+/-3%), the proportion of individuals who respond with a "take" 6 to 11 days after vaccination with undiluted Dryvax vaccine and Dryvax diluted at 1:5. A "take" is defined as the formation of a lesion at the site of vaccination that is consistent with the description of a successful vaccination described in the IB Secondary study objectives include defining with good precision (+/- 10%), the proportion of individuals who respond with a "take" 6 to 11 days after vaccination with a 1:10 dilution of Dryvax vaccine and exploring correlations between "takes"/ no-"take" and immune responses in all vaccine groups (antibody responses in all volunteers; and assays of cell-mediated immunity in a convenience sample consisting of 15 volunteers enrolled at each site (total N = 105) randomly distributed across the vaccine groups). Immunogenicity assays will include neutralizing antibody to vaccinia, vaccinia binding antibody, ELISPOT for gamma interferon [Assays of cell-mediated immunity will be performed only on a convenience sample consisting of 15 volunteers enrolled at each site (total N = 105)] and intracellular cytokine production. Primary safety endpoints include safety data regarding the three doses of vaccine in previously vaccinated subjects as assessed by adverse events reported by the subjects and/or investigators and changes observed during the scheduled clinic visits. Specific attention will be paid to the following: local reactogenicity at the site of injection: pain, tenderness, erythema, induration, regional lymphadenopathy, limitation of limb movement; systemic symptoms: fever, myalgia, fatigue, and headache; anaphylaxis, and hypersensitivity reactions; other reactions: dermatologic, neurologic, gastrointestinal (nausea/vomiting, diarrhea). The primary efficacy endpoint for this trial will be the proportion of vaccinees demonstrating a "take" 6 to 11 days after the first vaccination at each of the dose levels (undiluted and 1:5 and 1:10). Secondary endpoints are: immune responses as assessed by vaccinia neutralizing antibody measured on all subjects and binding antibody to vaccinia on all subjects and the size of the lesions observed in all subjects compared across the dilution groups. Tertiary endpoints of 15 volunteers at each site randomly distributed across the vaccine groups are cellular immune responses as assessed by: ELISPOT for gamma interferon in response to vaccinia antigens and intracellular cytokine production.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 927
• Est. completion date: December 2003
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 32 Years to 70 Years

Eligibility

Inclusion Criteria:

1. Age 32 to 70 years.

2. Typical vaccinia scar or validated documentation (e.g., military record, international travel certificate) of a smallpox vaccination, but not since 1989.

3. Willing to sign informed consent.

4. Availability for follow-up for the planned duration of the study (at least 26 weeks after vaccination).

5. Acceptable medical history by screening evaluation and brief clinical assessment.

6. Negative urine or serum pregnancy test for women of childbearing potential.

7. If the subject is female and of childbearing potential, she must use an acceptable contraception and not become pregnant within 56 days post vaccination. (Acceptable contraception includes implants, injectables, combined oral contraceptives, effective intrauterine devices (IUDs), sexual abstinence, or a vasectomized partner).

8. Negative ELISA for HIV or indeterminant Western blot or other assay confirming that the serostatus does not reflect HIV infection

9. ALT < 1.5 times institutional upper limit of normal.

10. Negative hepatitis B surface antigen and negative antibody to hepatitis C virus.

11. Negative urine glucose by dipstick.

12. Adequate renal function defined as a serum creatinine less than or equal to 1.5 mg/dL; urine protein < 100 mg/dL or trace or negative proteinuria by dipstick; and a calculated creatinine clearance > 55 mL/min based on the formulas in the manual of procedures.

13. Hematocrit > 34% for females, > 38% for males; platelets > 150,000/mm3; and WBC > 2,500/mm3 and < 11,000/mm3.

Exclusion Criteria:

1. Smallpox vaccination in 1990 or more recently.

2. History of immunodeficiency.

3. Known or suspected impairment of immunologic function including, but not limited to, clinically significant liver disease; diabetes mellitus; moderate to severe kidney impairment.

4. Malignancy, other than squamous cell or basal cell skin cancer.

5. Active autoimmune disease.

6. Use of immunosuppressive medication.

7. Medical or psychiatric condition or occupational responsibilities that preclude subject compliance with the protocol.

8. History of "illegal" injection drug use.

9. Inactivated vaccine 14 days prior to vaccination

10. Live attenuated vaccines within 60 days of study.

11. Use of investigational agents within 30 days prior to study.

12. Receipt of blood products or immunoglobulin in the past 6 months.

13. Acute febrile illness on the day of vaccination.

14. Pregnant or lactating women.

15. Eczema of any degree or history of eczema.

16. History of chronic exfoliative skin disorders/conditions.

17. Any acute skin disorders of large magnitude, e.g., laceration requiring sutures, burn greater than 2 x 2 cm.

18. Household contacts/sexual contacts with, or frequent and/or prolonged exposure to, any of the following:

• Pregnant women

• Children < 12 months of age

• People with or history of eczema

• People with chronic exfoliative skin disorders/conditions or any acute skin disorders of large magnitude. e.g., laceration requiring sutures, burn greater than 2 x 2 cm

• People with immunodeficiency disease or use of immunosuppressive medications

19. Any condition that, in the opinion of the investigator, might interfere with study objectives.

20. Known allergies to any component of the vaccine (e.g., polymyxin B sulfate, dihyrostreptomycin sulfate, chlortetracycline hydrochloride, neomycin sulfate).

21. Known allergies to any known component of the diluent (i.e., glycerin and phenol).

22. Known allergies to any known component of VIG, i.e., thimerosal or previous allergic reaction to immunoglobulins.

23. Known allergies to cidofovir or probenecid.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Smallpox

Intervention

Biological:
• Live vaccinia virus vaccine
Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
• Live vaccinia virus vaccine
Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.

Locations

Country	Name	City	State
United States	University of Maryland Baltimore	Baltimore	Maryland
United States	Duke Health Center	Durham	North Carolina
United States	Kaiser Permanente Vaccine Study Center	Oakland	California
United States	University of Rochester	Rochester	New York
United States	Saint Louis University	St. Louis	Missouri
United States	Stanford University	Stanford	California
United States	UCLA Center For Vaccine Research	Torrance	California

Sponsors (1)

Lead Sponsor	Collaborator
National Institute of Allergy and Infectious Diseases (NIAID)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Proportion of vaccinees demonstrating a "take" 6 to 11 days after the first vaccination at each of the dose levels (undiluted and 1:5 and 1:10).		6 to 11 days after the first vaccination at each of the dose levels (undiluted and 1:5 and 1:10).	No